Deep EigenMatics Tops 2025 Global AI Drug Discovery Patent Rankings
Deep EigenMatics has achieved the number one global ranking for new U.S. patent families in AI drug discovery methods for 2025, announced in a press release. The company, which began operations in 2025, secured four unique patent families covering its proprietary computational architectures for exploring chemical space.
The patents represent twice the combined output of all major pharmaceutical companies in the same category. Deep EigenMatics measured its performance using two internal metrics—Patent Family Volume and Innovation Velocity Index—indicating a high efficiency rate in its R&D operations.
Building on this momentum, the company has identified the Oral GLP-1 category as its lead therapeutic target. It plans to move into the execution phase for its Oral GLP-1 candidate, with a development roadmap extending through 2026 and 2027.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Sep 29 University Medical Center Göttingen Adopts MDClone Clinical Data Platform Sep 29 LUNGevity Awards $2 Million for Lung Nodule Risk Studies Sep 28 Deep Longevity to Launch Accrua Telehealth Platform in US Sep 28 United Imaging Intelligence Releases Medical Video AI Framework Sep 28 Orca Dental AI Brings CephX Imaging Tools to Planet DDS Cloud 9Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Probably Genetic Gets Up to $10M ARPA-H Contract for Rare Disease AI
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Sunthetics Joins $19.5M NSF Autonomous Lab Initiative
Inductive Bio launches Beacon-2 to predict human drug doses
Market Logic Software Launches DeepSights Radar for Market Monitoring
Daily AI Brief: the AI news that matters, in your inbox.